Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manfred Jung

Showing results (41-50 of 253) with videos related to

Pageof 26
Sort By:
ACS Pharmacology & Translational Science|February 21, 2022
Comparison of Cellular Target Engagement Methods for the Tubulin Deacetylases Sirt2 and HDAC6: NanoBRET, CETSA, Tubulin Acetylation, and PROTACsAnja Vogelmann, Manfred Jung, Finn K Hansen, et al.
Anticancer Research|August 15, 2002
Comparative action of cobalt carbonyl complexes on cancer cells using human tumor xenograftsThomas Roth, Chris Eckert, Heinz-Herbert Fiebig, et al.
Clinical Epigenetics|January 25, 2011
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapyJulia M Wagner, Björn Hackanson, Michael Lübbert, et al.
Future Medicinal Chemistry|November 20, 2012
Current trends in epigenetic drug discoveryDiana A Stolfa, Oliver Einsle, Wolfgang Sippl, et al.
Archiv Der Pharmazie|January 12, 2012
Small molecule inhibitors of histone acetyltransferases as epigenetic tools and drug candidatesSilviya D Furdas, Srinivasaraghavan Kannan, Wolfgang Sippl, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|March 12, 2025
The bioactivity of atraric acid as an inducer of cellular senescence in prostate cancer cells is retained by lipophilic derivativesAdina Asara Baniahmad, Golnaz Atri Roozbahani, Manfred Jung, et al.
Bioorganic & Medicinal Chemistry|February 15, 2011
Computer- and structure-based lead design for epigenetic targetsRalf Heinke, Luca Carlino, Srinivasaraghavan Kannan, et al.
Medicinal Research Reviews|January 18, 2017
The Current State of NAD<sup>+</sup> -Dependent Histone Deacetylases (Sirtuins) as Novel Therapeutic TargetsMatthias Schiedel, Dina Robaa, Tobias Rumpf, et al.
Biological Chemistry|June 24, 2003
Trichostatin A and structurally related histone deacetylase inhibitors induce 5-lipoxygenase promoter activityNiko Klan, Sabine Seuter, Nicole Schnur, et al.
Phytochemistry|August 22, 2009
The ergot alkaloid gene cluster: functional analyses and evolutionary aspectsNicole Lorenz, Thomas Haarmann, Sylvie Pazoutová, et al.
Pageof 26

Showing results (41-50 of 253) with videos related to

Sort By:
Pageof 26
ACS Pharmacology & Translational Science|February 21, 2022
Comparison of Cellular Target Engagement Methods for the Tubulin Deacetylases Sirt2 and HDAC6: NanoBRET, CETSA, Tubulin Acetylation, and PROTACsAnja Vogelmann, Manfred Jung, Finn K Hansen, et al.
Anticancer Research|August 15, 2002
Comparative action of cobalt carbonyl complexes on cancer cells using human tumor xenograftsThomas Roth, Chris Eckert, Heinz-Herbert Fiebig, et al.
Clinical Epigenetics|January 25, 2011
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapyJulia M Wagner, Björn Hackanson, Michael Lübbert, et al.
Future Medicinal Chemistry|November 20, 2012
Current trends in epigenetic drug discoveryDiana A Stolfa, Oliver Einsle, Wolfgang Sippl, et al.
Archiv Der Pharmazie|January 12, 2012
Small molecule inhibitors of histone acetyltransferases as epigenetic tools and drug candidatesSilviya D Furdas, Srinivasaraghavan Kannan, Wolfgang Sippl, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|March 12, 2025
The bioactivity of atraric acid as an inducer of cellular senescence in prostate cancer cells is retained by lipophilic derivativesAdina Asara Baniahmad, Golnaz Atri Roozbahani, Manfred Jung, et al.
Bioorganic & Medicinal Chemistry|February 15, 2011
Computer- and structure-based lead design for epigenetic targetsRalf Heinke, Luca Carlino, Srinivasaraghavan Kannan, et al.
Medicinal Research Reviews|January 18, 2017
The Current State of NAD<sup>+</sup> -Dependent Histone Deacetylases (Sirtuins) as Novel Therapeutic TargetsMatthias Schiedel, Dina Robaa, Tobias Rumpf, et al.
Biological Chemistry|June 24, 2003
Trichostatin A and structurally related histone deacetylase inhibitors induce 5-lipoxygenase promoter activityNiko Klan, Sabine Seuter, Nicole Schnur, et al.
Phytochemistry|August 22, 2009
The ergot alkaloid gene cluster: functional analyses and evolutionary aspectsNicole Lorenz, Thomas Haarmann, Sylvie Pazoutová, et al.
Pageof 26